Promomed Group: Geographic Expansion

The leadership read

Promomed has moved from a bilateral MoU signed in September 2025 into active ministry-level operational discussions, a materially different posture. The September agreement was witnessed ceremony; this meeting produced Drug Administration of Vietnam tasking on regulatory procedures, a named second distribution partner (CPC1 alongside Vinapharm), and a ministerial instruction to develop a strategic framework. The company has now committed to a multi-entity, multi-product regulatory pathway in a market with its own procurement rules, local content expectations, and a newly enacted Pharmaceuticals Law, none of which were on its plate before the 2025 MoU closed. This is one of 12 geographic expansion signals we have tracked across sectors in the last 90 days, though the comparable set is thin on pharma-to-Southeast-Asia specifically. The broader pattern is consistent: companies pairing a government-level relationship with a named local distribution partner are accelerating from soft entry to operational commitment faster than prior cycles suggested. Vietnam's active solicitation of technology-transfer manufacturing, biosimilars and monoclonal antibodies in particular, is drawing producers who can offer both product and process, not just import volume. Companies reaching this stage of government-partnered pharma expansion in Southeast Asia face concentrated demand for regulatory affairs leadership fluent in ASEAN registration pathways, commercial operations capable of managing multi-distributor channel conflict, and technology-transfer program management with local manufacturing integration experience. That functional combination is structurally scarce in the Russia-Vietnam corridor specifically.